This study is looking at two different treatments for high-risk basal cell carcinoma (a type of skin cancer) that can be removed by surgery. You might be eligible if you are 18 or older and have a basal cell carcinoma that is 20 mm or larger on your head/neck, or 40 mm or larger on your body/limbs. The study compares Nivolumab alone to a combination of Relatlimab plus Nivolumab (Opdualag). Both treatments work by blocking signals that can stop your immune system from fighting cancer. Researchers will give you one of these treatments for about 4 cycles before surgery, and they will measure how much the cancer shrinks or disappears. The goal is to see which treatment leads to a better response in the cancer before surgery, and how well patients do over two years.

Study design

This is a Phase 2 study where participants are randomly assigned to receive either Nivolumab or Relatlimab plus Nivolumab (Opdualag). About 30 people are planned to join this study.

What's involved

Participants will receive 4 cycles of treatment every 4 weeks before surgery. There is an option to have surgery earlier or continue treatment longer, depending on how you respond.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for disease recurrence and other outcomes for at least 2 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.